The Future Moment

MODULE 8 PREVIEW PACK, The Future Moment
For NotebookLM: generate a 15-20 minute synthesis episode.
Format: Two hosts take stock of where the field stands in 2026, what has changed, what hasn't, and what the most important open questions are for writers covering this space.

---

WHERE WE ARE IN 2026: THE CLINICAL PICTURE

Psilocybin: A psilocybin developer has completed two Phase 3 trials (the first, June 2025; the second, February 2026) for treatment-resistant depression. Both met primary endpoints. NDA submission targeted Q4 2026. Potential FDA approval: late 2026 or early 2027. Usona Institute's Phase 3 trial for major depressive disorder (not treatment-resistant) is ongoing. Australia approved psilocybin for clinical use in February 2023.

MDMA: FDA rejected the sponsor's MDMA application in August 2024 on methodological grounds (unblinding, therapist expectancy). Additional Phase 3 trial requested. Australia approved MDMA for PTSD in February 2023.

LSD: Phase 2 trials ongoing in Switzerland, Canada, UK. Holze et al. (Basel, 2023) showed antidepressant effects in Phase 2. No commercial sponsor for Phase 3 yet.

Ibogaine: Texas $50M research mandate for veterans (2025). Mississippi ibogaine research bill (March 2026). No FDA approval pathway established.

Ketamine/Esketamine: esketamine nasal spray (esketamine) is FDA-approved for treatment-resistant depression under REMS program since 2019. Hundreds of ketamine clinics operating in the US, most without FDA approval for depression indication.

WHERE WE ARE IN 2026: THE POLICY PICTURE

Oregon: Measure 109 psilocybin services program operational with 100+ licensed service centers. Measure 110 decriminalization repealed 2024. Program modified March 2026.
Colorado: Proposition 122 healing centers operational since July 2025. Personal decriminalization of psilocybin, ibogaine, DMT, mescaline in effect.
New Mexico: Medical psilocybin program operational 2025. First state to pass through legislature rather than ballot.
Texas: $50M ibogaine research for veterans. No personal use decriminalization.
Federal: Cannabis rescheduling from Schedule I to Schedule III proposed May 2024, not yet final as of June 2026.

THE OPEN QUESTIONS WORTH WRITING ABOUT

1. THE EQUITY QUESTION: Who will have access to approved psilocybin therapy? synthetic psilocybin, if approved, will cost more than SSRI antidepressants and require certified clinical settings and trained therapists. Insurance coverage is uncertain. The communities most harmed by the drug war are least likely to access the therapeutic benefits of the psychedelic renaissance. Is this outcome inevitable or preventable?

2. THE INDIGENOUS RIGHTS QUESTION: Every approved psychedelic compound is derived from or structurally related to compounds used by indigenous communities for millennia. The psychedelic patent race (one developer's crystal polymorph patents, etc.) is creating intellectual property over compounds that indigenous communities have stewarded without IP protection. The Nagoya Protocol provides partial protection. Is it enough?

3. THE METHODOLOGY QUESTION: The FDA's MDMA rejection raised legitimate methodological concerns about blinding in psychedelic trials. How do you design a rigorous clinical trial of a substance where both participants and therapists know whether active drug was administered? This is not a solved problem.

4. THE INTEGRATION QUESTION: The clinical evidence shows that mystical experience quality predicts outcomes. But the "integration" of mystical experience, incorporating it into how a person actually lives, is a separate project from having the experience. What therapeutic infrastructure exists for this, and is it adequate?

5. THE CULTURAL QUESTION: Is the current psychedelic renaissance producing the cultural reorientation that Huxley, Hofmann, McKenna, and Narby thought these substances could produce? Or is it producing a more sophisticated version of the same consumer capitalism? Who decides?

MODULE 8 DEBATE PACK, The Most Important Question
For NotebookLM: generate a 18-22 minute debate episode.
Format: Two hosts genuinely disagree about which open question in the psychedelic field is most important for writers to engage with now. Each argues for their position with evidence. The debate should not resolve cleanly.

---

POSITION A: THE EQUITY QUESTION IS THE MOST IMPORTANT

Argument: Everything else is downstream of who has access.

The clinical evidence for psilocybin-assisted therapy is strong enough that approval is likely in 2026-2027. synthetic psilocybin, if approved, will be the first psychedelic-assisted therapy with full FDA approval. The question of who has access to this treatment will determine whether the psychedelic renaissance produces justice or the reverse.

The drug war's primary harm fell on Black and Latino communities, 3.73x disproportion in marijuana arrests for similar use rates. Oregon's cannabis industry, the cannabis industry nationally, and emerging psychedelic service industries have all failed to direct proportionate benefit to the communities most harmed by prohibition.

If psilocybin-assisted therapy becomes a treatment for depression available primarily to people with good insurance, high incomes, and access to certified clinical settings in urban areas, while the communities most targeted by the drug war cannot access it, then the psychedelic renaissance will have produced a boutique medical intervention rather than a reckoning with the injustice it was supposed to address.

This is not speculative. Oregon's Measure 109 service centers cost $300-$2,000 per session out of pocket. No insurance coverage as of 2026. The equity gap is already present.

POSITION B: THE METHODOLOGY QUESTION IS THE MOST IMPORTANT

Argument: If the clinical trials can't meet methodological standards, nothing else matters.

The FDA's August 2024 rejection of MDMA-assisted therapy was not a rejection of the science, the Phase 3 efficacy data was significant. It was a rejection of the methodology: the trials could not adequately blind participants, therapist expectancy bias was uncontrolled, adverse event characterization was inadequate.

The same methodological challenge applies to every psychedelic trial: participants who receive active drug almost always know they've received it. This is the unblinding problem, and it is not solved. If the therapeutic benefit comes partly from expectation, which the set and setting literature suggests it does, then placebo-controlled trials may be structurally unable to isolate the pharmacological effect.

This matters for everything downstream of approval: if the methodology can't meet FDA standards, there are no approvals; if there are no approvals, there's no insurance coverage; if there's no insurance coverage, the equity question is moot because only the wealthy can access unregulated services.

The solution to the unblinding problem, active placebos that mimic the phenomenological effects without the therapeutic ones, is the most important technical challenge in the field. The 2025-2026 trials have not solved it.

POSITION C (MODERATOR): NEITHER IS THE MOST IMPORTANT

What if the most important question is the one neither of you is asking?

The cultural question: is the psychedelic renaissance producing the cultural transformation that its proponents claim these substances are capable of producing? Or is it producing a sophisticated pharmaceutical and wellness industry that monetizes altered consciousness without disrupting the systems that create the conditions driving depression, addiction, and anxiety in the first place?

McKenna argued that the dominator culture would consume any medicine that threatened it. The evidence from 2026 suggests he was right. The psychedelic renaissance has produced: branded microdosing products, $500-per-night retreat centers, FDA-approved pharmaceutical analogues, Silicon Valley productivity protocols, and venture-backed biotech companies.

None of these are the Archaic Revival. All of them are the dominator culture adapting to a new market.

The most important question for writers is not who gets access to the treatment or whether the trials are methodologically sound. It's whether the treatment is being developed in a way that addresses what created the need for it, or whether it's being developed in a way that leaves the underlying conditions intact while adding a new product category.